Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00790 (
PGA
)
2,475
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cross-linked poly-gamma-glutamic acid (C-L gamma-
PGA
) at 5 microg/ml flocculated bentonite suspension pretreated with polyaluminum chloride (PAC) at 2 microg/ml Al3+-PAC to a transparency of approximately 30% after 30 min and more than 90% after 4 h, while Al3+ concentration in the upper phase of the suspension decreased with incubation time. When pretreated with
FeCl3
at 16 microg/ml Fe3+-
FeCl3
, similar results were obtained. In the case of Escherichia coli suspension, the combination of C-L gamma-
PGA
and
FeCl3
demonstrated a more marked flocculating activity with a satisfactory transparency occurring after 30 min of treatment, accompanied by a decrease in residual Fe3+ concentration. In the above two suspensions pretreated with
FeCl3
, small visible floats appeared in the early stage of incubation. These floats were found to be due to the direct interaction between
FeCl3
and C-L gamma-
PGA
, indicating the formation of a water-insoluble complex. After allowing the suspension to stand for a long time, elemental analysis and inductively coupled plasma spectroscopy of the precipitates produced suggested that not only the complex was formed due to the interaction between Fe3+ in
FeCl3
and COO- in the C-L gamma-
PGA
molecule, but also Fe2O3 and Fe(OH)3 might be entrapped in this complex. This could be applied to scavenge metal ions including Fe3+ from polluted water.
...
PMID:Flocculating activity of cross-linked poly-gamma-glutamic acid against bentonite and Escherichia coli suspension pretreated with FeCl3 and its interaction with Fe3+. 1619 66